donor-derived CD5 CAR T cells

This is an investigational allogeneic (donor-derived) CAR T-cell therapy targeting the CD5 antigen, primarily developed for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL). Developed through a collaboration between Zhujiang Hospital, Beijing Boren Hospital, Gobroad Medical Group, and the Institute of Hematology and Blood Diseases Hospital, the therapy utilizes T cells from either a previous stem cell transplant donor or a newly matched donor. To address the challenge of T-cell fratricide—where CAR T cells attack each other due to the shared expression of CD5—the CD5 gene is deleted from the therapeutic cells using CRISPR-Cas9 gene editing technology. Administered intravenously, this therapy has demonstrated high rates of complete remission in Phase 1 clinical trials, particularly in patients who have relapsed after CD7-targeted CAR T-cell therapy or those with CD7-negative disease.

Other names

allogeneic CD5-targeted CAR T-cell therapyCD5-targeted CAR T cellsCD-5-targeted CAR T cellsCD 5-targeted CAR T cellsCRISPR-Cas9 edited CD5 CAR T cellsCRISPR-Cas-9 edited CD5 CAR T cellsCRISPR-Cas 9 edited CD5 CAR T cellsdonor-derived CD5-targeted CAR T-cell therapy